ResMed: CEO History

ResMed Inc. (NYSE: RMD) is a global pioneer in connected medical devices and digital health solutions, headquartered in San Diego, California. Founded in 1989 by Dr. Peter Farrell, ResMed transformed the diagnosis and treatment of obstructive sleep apnea (OSA), chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Operating across two primary business segments—Sleep and Respiratory Care (~88% of revenue, encompassing continuous positive airway pressure [CPAP] generators, bilevel devices, and specialized patient masks) and Out-of-Hospital Software-as-a-Service (~12% of revenue, including Brightree, MatrixCare, and MEDIFOX DAN)—ResMed serves clinicians, home medical equipment (HME) providers, and patients across 140 countries. At the heart of ResMed's modern competitive advantage is its digital health ecosystem: over 20.5 million cloud-connectable devices deployed globally transmit nightly sleep therapy data to the proprietary AirView cloud platform. This allows physicians and home health providers to monitor patient compliance remotely, anticipate equipment maintenance, and satisfy health insurer reimbursement criteria without manual data card downloads. Under the visionary leadership of Chairman and CEO Mick Farrell, ResMed captured decisive market share following the catastrophic global product recall of rival Philips Respironics, while aggressively reinvesting in AI-driven sleep diagnostics, personalized digital coaching apps (myAir), and expanding post-acute care SaaS solutions. ResMed represents an institutional pillar within its global sector, maintaining expansive operations, robust customer and partner relationships, and mission-critical operating infrastructure. Operating on a significant scale across domestic and international markets, ResMed continues to expand its technological and operational capabilities, integrating automated digital workflows, enterprise-grade data security protocols, and advanced operational systems to maximize service reliability and long-term operating efficiency. The enterprise remains focused on capital discipline, scalable operational economics, and strategic customer expansion across high-value market segments. continuous investment in specialized research, modern distribution networks, and skilled workforce development enables ResMed to anticipate regulatory changes, mitigate emerging market risks, and deliver dependable performance for millions of clients, patients, or consumers worldwide.